AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer Ruchika Sharma3 March 2025 12:15 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union...
IHH Healthcare Seeks USD 1.7 Billion from Daiichi Sankyo Over Fortis Deal Disruption Farhat Nasim8 Feb 2025 4:34 PM ISTDelhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, demanding compensation of...
Daiichi Sankyo names Hiroyuki Okuzawa as CEO Ruchika Sharma3 Feb 2025 1:30 PM ISTTokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer...
Roche bags USFDA nod for companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu Ruchika Sharma1 Feb 2025 12:30 PM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5)...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer Ruchika Sharma28 Jan 2025 2:30 PM ISTAstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with...
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer Ruchika Sharma20 Jan 2025 3:01 PM ISTTokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult...
AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA priority review in pretreated EGFR-mutated non-small cell lung cancer Ruchika Sharma14 Jan 2025 2:30 PM ISTDatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo.
Daiichi Sankyo Datroway approved in Japan for breast cancer Ruchika Sharma29 Dec 2024 12:00 PM ISTTokyo: Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor...
AstraZeneca, Daiichi Sankyo voluntarily withdraws datopotamab deruxtecan application in EU for lung cancer Ruchika Sharma25 Dec 2024 11:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab...
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list Ruchika Sharma29 Nov 2024 5:29 PM ISTChina: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance scheme from January 1, as per...
AstraZeneca, Daiichi Sankyo submits Datopotamab deruxtecan new BLA for accelerated approval in US for lung cancer Ruchika Sharma14 Nov 2024 3:15 PM ISTAstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan...
Fortis trademark to be auctioned: HC order Ruchika Sharma30 Oct 2024 2:45 PM ISTNew Delhi: In connection with the Rs 3,500 crore arbitral award passed in favour of Daiichi Sankyo and against the former Ranbaxy promoters,...
